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Abstract
Background: We determined the association between ratios of plasma ceramide
species of differing fatty-acyl chain lengths and incident dementia and Alzhei-
mer’s disease (AD) dementia in a large, community-based sample. Methods:
We measured plasma ceramide levels in 1892 [54% women, mean age 70.1 (SD
6.9) yr.] dementia-free Framingham Offspring Study cohort participants
between 2005 and 2008. We related ratios of very long-chain (C24:0, C22:0) to
long-chain (C16:0) ceramides to subsequent risk of incident dementia and AD
dementia. Structural MRI brain measures were included as secondary outcomes.
Results: During a median 6.5 year follow-up, 81 participants developed demen-
tia, of whom 60 were diagnosed with AD dementia. In multivariable Cox-pro-
portional hazards analyses, each standard deviation (SD) increment in the ratio
of ceramides C24:0/C16:0 was associated with a 27% reduction in the risk of
dementia (HR 0.73, 95% CI 0.56–0.96) and AD dementia (HR 0.73, 95% CI
0.53–1.00). The ratio of ceramides C22:0/C16:0 was also inversely associated
with incident dementia (HR per SD 0.75, 95% CI 0.57–0.98), and approached
statistical significance for AD (HR 0.73, 95% CI 0.53–1.01, P = 0.056). Higher
ratios of ceramides C24:0/C16:0 and C22:0/C16:0 were also cross-sectionally
associated with lower white matter hyperintensity burden on MRI
(0.05  0.02, P = 0.02; 0.06  0.02, P = 0.003; respectively per SD
increase), but not with other MRI brain measures. Conclusions: Higher plasma
ratios of very long-chain to long-chain ceramides are associated with a reduced
risk of incident dementia and AD dementia in our community-based sample.
Circulating ceramide ratios may serve as potential biomarkers for predicting
dementia risk in cognitively healthy adults.
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Introduction
Discovering novel blood-based biomarkers for dementia
can identify disease at an early preclinical stage, serve as
surrogate outcomes for clinical trials of investigational
therapies and inform our understanding of the underlying
biological pathways of disease onset and progression.
Altered lipid metabolism is believed to play an important
role in the development of dementia and Alzheimer’s dis-
ease (AD).1–3 Ceramides are molecular species belonging
to the sphingolipid family, consisting of a sphingoid base
coupled with a fatty acyl chain, differing from each other
according to the length of the fatty acyl chain.4 They are
generated through three pathways, that is, the cleavage of
sphingomyelin by sphingomyelinases, the salvage of
breakdown products of complex sphingolipids, and de
novo synthesis via a family of six ceramide synthase
enzymes.5 Ceramides play roles in low density lipoprotein
aggregation,6 inflammation,7 endothelial dysfunction,8
and cell proliferation, differentiation and apoptosis,
including neuronal cell death.9–11 Total plasma ceramide
concentrations have been suggested as potential early
blood-based biomarkers for predicting mild cognitive
impairment and progression to dementia.12 Prior studies
have reported an association between higher plasma cera-
mide concentrations and hippocampal atrophy,1 cognitive
decline,13 as well as all-cause dementia and AD dementia,
although results have been conflicting between men and
women.14,15 Additionally, many of these studies were lim-
ited by smaller sample sizes and a cross-sectional design.
Recently, attention has focused on the role of circulating
ratios of a very-long-chain to long-chain ceramides as
biomarkers for major vascular events16,17 and the possibility
that these ratios may be of greater diagnostic and prognostic
value for cardiovascular outcomes compared to total cera-
mide levels or concentrations of individual ceramide species.
It has been contended, but is unproven, that the adverse cog-
nitive effects of ceramides may be related to the relative pro-
portions of circulating very long-chain to long-chain fatty
acyl chains rather than simply due to elevated total ceramide
levels.18,19 In the present investigation, we related circulating
ratios of previously measured very long-chain to long-chain
ceramides17 to MRI structural brain measures (cross-section-
ally) and amyloid burden on brain-PET (longitudinally),
and to the incidence of clinically confirmed dementia and
AD dementia prospectively in a large, community-based,
sample of relatively healthy adults.
Methods
Study sample
The Framingham Offspring cohort is a longitudinal epi-
demiological study of individuals recruited between 1971
and 1975. This large, predominantly middle-aged cohort
has been prospectively followed for the development of vas-
cular risk factors, decline in cognitive function, dementia
and stroke for over 45 years.20 Each participant is evaluated
at approximately 4-year intervals from the time of enroll-
ment into the cohort. In the present investigation, we
included participants from the Offspring cohort who
attended their eight quadrennial examination cycle (2005–
2008), were aged 60 years or above and free of dementia at
this exam, and who had data available on dementia status
at follow-up and had undergone plasma ceramide measure-
ments at that examination. All participants provided writ-
ten informed consent. The institutional review board at
Boston University Medical Center approved the study pro-
tocol. Of the original Offspring cohort (n = 5124), 3021
were alive and attended examination eight, 2008 of whom
were aged 60 years or above, confirmed free of dementia
and with available dementia status on follow-up. Of these,
1892 had plasma ceramides measured at examination eight,
resulting in the sample for the present investigation
(Fig. 1). For the cross-sectional analyses of structural MRI
brain measures, we included those participants in the
dementia cohort who had an MRI brain completed at exam
eight (n = 1541 [81% of the dementia cohort]) and had
available plasma ceramide measurements. For analyses of
amyloid-burden on brain-PET, we included participants in
the dementia cohort who had available PET data at exam
nine (n = 48).
Outcome measures
Our primary outcome measure was incident all-cause
dementia developing at any time after the 8th examina-
tion cycle and up to the end of 2016. From examination
cycle five (1991–1995) onward, all participants in the Off-
spring cohort were systematically screened using the
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Mini-Mental State Examination (MMSE) and annual
health status updates for the development of dementia.
From examination cycle seven onward, we invited all par-
ticipants to complete neurocognitive testing. We com-
pleted more detailed cognitive testing in those cases
where the participant’s MMSE score was lower than the
education-based cut-off, three points lower than the pre-
ceding examination, or five points lower than the previ-
ous highest recorded score or if the participant, family
member, or Framingham study physician was concerned
about cognitive impairment.21 If a participant had sus-
pected cognitive impairment but did not meet criteria for
a diagnosis of dementia, additional yearly neuropsycho-
logical assessments were performed between the quadren-
nial Offspring examinations. A diagnosis of dementia was
based on the Diagnostic and Statistical Manual of Mental
Disorders (4th edition) criteria requiring impairment in
memory and at least one other domain of cognitive func-
tion, along with impaired functional ability. Adjudication
of dementia, and date of diagnosis, was reached by a
committee comprising of at least one neuropsychologist
and one neurologist after a detailed review of all available
neurological examination records, neuropsychological
assessments, neuro-imaging data, hospital/nursing home/
outpatient clinic records, information from family inter-
views, and autopsy results (when available). AD dementia
was included as an additional primary outcome measure.
A diagnosis of AD dementia was reached based on the
criteria of the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association for definite,
probable, or possible Alzheimer’s disease.22
We evaluated structural MRI brain measures in sec-
ondary analyses, including total parenchymal brain vol-
ume (TBV), hippocampal volume (HV), white matter
hyperintensity volume (WMHV) and covert brain infarcts
(CBI). MRI imaging was performed using a Siemens
Avanto 1.5 Tesla machine. More detailed methods on
MRI brain measures have previously been published.23 In
brief, TBV was defined as supratentorial brain volume as
a percentage of the intracranial volume, determined from
coronal sections. White matter hyperintensity volume
(WMHV) was performed on a combination of FLAIR
and 3D T1 images using a modified Bayesian probability
structure based on a previously published method of his-
togram fitting.24 Cerebral volumes were calculated as a
percentage of intracranial volume and then natural loga-
rithmically transformed to approximate a normal distri-
bution. Hippocampal volume (also calculated as a
percentage of intracranial volume) was measured using an
automatic hippocampal segmentation method employing
a standard atlas-based diffeomorphic approach,25 which
was modified to include the European Alzheimer’s Dis-
ease Consortium-Alzheimer’s Disease Neuroimaging Ini-
tiative (EADC-ADNI) harmonized hippocampal masks.
The presence of CBI was manually determined based on
the size (≥3 mm), location and imaging characteristics of
the lesion according to the STandards for ReportIng Vas-
cular changes on nEuroimaging (STRIVE) criteria,26 with
documented good interrater reliability.27,28 Imaging data
were centrally processed at the Imaging of Dementia and
Aging (IDeA) laboratory located at UC Davis and ana-
lyzed by operators blinded to all participant characteris-
tics including ceramide levels. We included amyloid-PET
burden using 11-C PiB as a secondary outcome measure
in exploratory analyses (see Appendix for further details).
Measurement of plasma ceramides
Fasting blood samples were drawn from participants in
the early morning, centrifuged and stored at 80°C until
assays were performed. A modified and fully validated
two-dimensional liquid chromatography-tandem mass
Figure 1. Sample selection for present investigation.
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spectrometry (LC–MS) assay was used to quantify plasma
levels of ceramides C24:0, C22:0, and C16:0 according to
previous published methods.17 Linear dynamic ranges for
ceramides C16:0, C22:0, and C24:0 in this assay were 0.01
to 2, 0.04 to 8, and 0.1 to 20 µg/mL, respectively. The
intraassay and interassay precisions were within 6.9%,
7.6% and 7.8% coefficient of variation for C24:0, C22:0
and C16:0, respectively.17
Covariates
We adjusted for baseline demographics and covariates
(measured at examination cycle eight), which have previ-
ously been associated with plasma ceramide ratios and
risk of dementia17,29 (variables were selected based on
clinical importance and evidence of prior associations),
including age, sex, education (self-reported and catego-
rized as: no high school degree, high school degree but
no college degree, some college but no degree, college
degree or higher), systolic blood pressure/use of antihy-
pertensive medication, apolipoprotein E4 (ApoE4) carrier
status (a carrier was defined as E2/E4, E3/E4 or E4/E4; a
noncarrier was defined as E2/E2, E2/E3 or E3/E3), preva-
lent cardiovascular disease (CVD, which included periph-
eral vascular disease [including intermittent claudication];
coronary artery disease [including coronary insufficiency,
angina, myocardial infarction]; and cerebrovascular dis-
ease [including transient ischemic attack and stroke]; and
congestive heart failure]), ratio of total cholesterol to
high-density lipoprotein cholesterol (TC:HDL-C), serum
triglycerides, and use of lipid-lowering therapies.
Statistical analysis
We standardized ceramide values to facilitate comparisons
as continuous variables. Multivariable Cox proportional
hazards models were estimated to evaluate the association
between circulating ceramide ratios and risk of incident
all-cause dementia and AD dementia. Participants were
followed from the baseline examination cycle eight to the
time of the incident event. For individuals without inci-
dent events, follow-up was censored at the time of death
or the date the participant was last known to be dementia
free, through December 2016. The assumption of propor-
tionality of hazards was confirmed, and results are
reported as hazard ratios (HR) with corresponding 95%
confidence intervals (CI). Model one adjusted for age and
sex, and model two additionally adjusted for education,
systolic blood pressure, use of antihypertensive medica-
tion, prevalent CVD, ApoE4 carrier status; TC:HDL ratio,
use of lipid-lowering therapies, and serum TG.
We estimated logistic (for binary outcomes) and linear
(for continuous measures) regression models to evaluate
the cross-sectional associations between circulating cera-
mide ratios and MRI-based structural brain measures,
including CBI, WMHV, TBV, and HV. Models were
adjusted for age, age squared (given age and brain vol-
ume show a nonlinear association), sex, time from blood
draw to MRI brain, use of antihypertensive medication,
systolic blood pressure, prevalent cardiovascular disease,
TC:HDL ratio, use of lipid-lowering therapies, and serum
TG. We investigated for interactions between ceramide
ratios and sex, ApoE4 carrier status and TC:HDL-C ratio
(<4:1 vs. ≥4:1) for the primary outcome of incident
dementia. We also completed a sensitivity analysis
excluding those with a history of prior stroke (n = 52).
Our primary, a priori, analyses evaluated the associations
between the ratio of ceramides C24:0 to C16:0 and C22:0
to C16:0 and risk of incident dementia. In secondary (ex-
ploratory) analyses, we related plasma concentrations of
individual ceramide species (i.e., C16:0, C22:0 and C24:0)
to the risk of incident dementia and AD dementia
prospectively, and with structural MRI brain measures,
cross-sectionally. In addition, we estimated multivariable
linear regression models to relate plasma ceramide ratios
and species to amyloid-PET burden, adjusting for age,
sex, and time from blood draw to PET scan. A two-sided
P < 0.05 was considered statistically significant. We com-
pleted all analyses using SAS version 9.4 (SAS Institute
Inc., Cary, NC).
Results
Our sample included 1892 eligible participants. The mean
age of the cohort was 70.1 (SD 6.9) years and 54% were
women. Baseline characteristics are shown in Table 1.
Ceramide ratios and incident dementia
During a median follow up of 6.5 (IQR 5.5–7.7) years, 81
individuals were diagnosed with dementia, 60 of whom
had AD dementia. In multivariable Cox-proportional haz-
ards regression models adjusted for demographics, vascu-
lar risk factors, use of lipid-lowering therapies and ApoE4
carrier status, the ratio of ceramides C24:0/C16:0 was
inversely associated with incident dementia (Hazards ratio
[HR] per each standard deviation [SD] increment 0.73,
95% CI 0.56–0.96, P = 0.023) and AD dementia (HR
0.73, 95% CI 0.53–1.00, P = 0.050). The ratio of cera-
mides C22:0/C16:0 was also inversely associated with inci-
dent dementia (HR per SD 0.75, 95% CI 0.57–0.98,
P = 0.038), but not AD dementia (HR per SD 0.73, 95%
CI 0.53–1.01, P = 0.056) (Table 2). A sensitivity analysis
excluding those with prior stroke showed results consis-
tent with our primary analyses. There was no statistically
significant interaction according to sex, ApoE4 carrier
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status or TC:HDL-C ratio for the risk of dementia associ-
ated with any of the ceramide levels or ratios.
Ceramide ratios and MRI and PET brain
measures
In multivariable analyses adjusting for age, age squared,
sex, time from blood draw to MRI brain, systolic blood
pressure, use of antihypertensive medication, prevalent car-
diovascular disease, TC:HDL ratio, use of lipid-lowering
therapies, and serum TG, each standard deviation incre-
ment in the ratio of ceramides C24:0/C16:0 and C22:0/
C16:0 was associated with lower WMHV (b  SE,
0.05  0.02, P = 0.02; 0.06  0.02, P = 0.003; respec-
tively; Table 3). Ceramide ratios were not cross-sectionally
associated with hippocampal volume, total brain volume or
with number of covert brain infarcts on brain MRI. In an
exploratory analysis among 48 individuals with available
PiB-PET data, each SDU increment in the ratio of ceramide
24:0/16:0 was associated with a reduced burden of ß-amy-
loid on PET (0.12  0.06, P = 0.05) (Table S1).
Secondary analyses - individual ceramide
species
In secondary analyses of individual ceramide species, higher
concentrations of ceramide C16:0 were also independently
associated with an increased risk of AD dementia (HR per
SD 1.49, 95% CI 1.08–2.06, P = 0.01) but not overall
dementia (HR per SD 1.21, 95% CI 0.92–1.61, P = 0.18).
None of the other ceramide species was individually associ-
ated with dementia risk (Table S2). Higher plasma cera-
mide C16:0 concentrations were also cross-sectionally
associated with a greater volume of white matter hyperin-
tensities on MRI brain (per SD increment, ß  SE,
0.05  0.03, P = 0.04, Table S3). None of the individual
plasma ceramides species was independently associated
with ß-amyloid burden on brain PET (Table S1).
Discussion
In the present investigation, higher ratios of very long-
chain to long-chain ceramides were associated with a
lower risk of dementia (C24:0/C16:0 and C22:0/C16:0)
and AD dementia (C24:0/C16:0) prospectively, as well as
with a lower burden of white matter disease on MRI
brain and B-amyloid burden on PET (C24:0/C16:0).
Previous studies have reported conflicting findings
regarding the association between individual plasma
Table 1. Baseline characteristics.
Variable Overall (n = 1892)
No. (%)
Age, y, mean (SD) 70.1 (6.9)
Women 1022 (54.0)
Systolic blood pressure, mmHg, mean (SD) 130.3 (17.1)
Ceramide 16:0, lg/mL (Q1, Q3) 0.16 (0.14, 0.19)
Ceramide 22:0, lg/mL (Q1, Q3) 0.59 (0.49, 0.71)
Ceramide 24:0, lg/mL (Q1, Q3) 2.17 (1.81, 2.60)
Ceramide 24:0/16:0 13.43 (11.64–15.67)
Ceramide 22:0/16:0 3.65 (3.16–4.21)
TC, mg/dL, mean (SD) 183.3 (37.0)
HDL, mg/dL, mean (SD) 57.1 (18.2)
TC:HDL, mean (SD) 3.44 (1.04)
TG, mg/dL, mean (SD) 117.7 (68.2)
Education
No high school degree 80 (4.3)
High school degree 553 (29.6)
Some years of college 567 (30.4)
College degree 668 (35.8)
Anti-hypertensive medication 1022 (54.1)
Lipid lowering therapy 892 (47.2)
ApoE4 allele carrier 398 (21.7)
Prevalent CVD 351 (18.6)
Prior stroke 52 (2.7%)
Baseline demographic and clinical characteristics were defined at
examination 8.
Abbreviations: SD, standard deviation; CVD, cardiovascular disease;
APOE E4, apolipoprotein E4 allele carrier (defined as E2/E4, E3/E4 or
E4/E4).
Table 2. Ceramide ratios and risk of incident dementia and AD dementia.
All-cause dementia Alzheimer’s disease dementia
Model 1 Model 2 Model 1 Model 2
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Ceramide 24:0/16:0 0.76 (0.59–0.98) 0.03 0.73 (0.56–0.96) 0.023 0.77 (0.57–1.04) 0.08 0.73 (0.53–1.00) 0.050
Ceramide 22:0/16:0 0.80 (0.62–1.03) 0.08 0.75 (0.57–0.98) 0.038 0.80 (0.59–1.07) 0.13 0.73 (0.53–1.01) 0.056
HR is reported per standard deviation unit increment in ceramide ratio.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, education, systolic blood pressure, use of antihypertensive medication, prevalent cardiovascular disease, and
ApoE4 carrier status, TC:HDL ratio, use of lipid-lowering therapies and serum TG.
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ceramide species and the risk of AD dementia. Some
studies have reported an association of both elevated
long-chain ceramides (C16:0)1,14,15 and very long-chain
ceramides (C22:0 and C24:0)14,15 with the risk of demen-
tia or AD dementia, whereas others observed no associa-
tion of very long-chain ceramides1 with dementia risk.
Some of these studies were limited by their cross-sectional
design or small sample sizes. In addition, results have var-
ied across tertiles of ceramide levels and according to sex,
with positive associations noted in women in one study,14
but only in men in a second study.15 To our knowledge,
there have been no prior studies to date exploring the
relationship between ratios of ceramides of varying fatty
acyl chain length and the subsequent risk of dementia.
For each standard deviation, increment in the ratio of
ceramides C24:0 to C16:0 and C22:0 to C:16:0, there was
an approximate 25% lower risk of developing dementia
in our investigation. We did not observe an interaction
according to sex for the risk of all-cause dementia associ-
ated with any of the ceramide levels or ratios.
Individual ceramide species are believed to have differ-
ent functions according to their length of fatty acyl chain.
While very long-chain fatty acyl ceramides are important
for myelin function and have been suggested to protect
against dementia,18 long-chain ceramide species have been
linked with deleterious proinflammatory and apoptotic
effects.11,18,30 Abnormalities in the myelin sphingolipid
pathway, including the synthesis of very long-chain cera-
mides, have been shown to occur in preclinical and clini-
cal stages of AD dementia. Reduced ceramide synthase-2
activity (the enzyme responsible for catalyzing the pro-
duction of very long-chain ceramides), has been found in
early Braak stages I/II in the temporal cortex and in stages
III/IV in the frontal cortex and hippocampus of human
brain tissue.19 In addition, severe depletion of sulfatide
and galactosylceramide, and their direct precursor, very
long-chain ceramides, has also been found in AD brain
tissue, along with a corresponding increase in the propor-
tion of long-chain ceramide species.19 Our findings of an
increased risk of dementia in those with lower levels of
circulating very long-chain ceramides relative to long-
chain ceramides are consistent with these findings and
may suggest a deleterious effect of long-chain ceramides
and an apparent protective effect of very long-chain cera-
mides on the risk of dementia. If confirmed, our findings
raise the possibility that circulating ceramide ratios may
be useful predictors of adverse cognitive outcomes and
may offer predictive utility in the early or even preclinical
stages of dementia.
Recent cardiovascular studies have consistently shown
an increased risk of adverse vascular events and mortality
in individuals with increased ratios of long-chain to very
long-chain ceramides in plasma.5,17,31–33 In a murine
model of ceramide synthase 2 haploinsufficiency, a reduc-
tion in levels of very long-chain (C22:0 and C24:0) cera-
mides and a compensatory increase in levels of long-
chain ceramides (C16:0) was noted, resulting in an
increased susceptibility to insulin resistance and hepato-
cyte apoptosis.30 Given the role of ceramides in pancreatic
b-cell dysfunction, insulin resistance and vascular reactiv-
ity,34 increased cardiometabolic risk could potentially
mediate the association with dementia. Indeed, we
observed that higher levels of ceramides C24:0 and C22:0
relative to C16:0 were associated with a lower burden of
white matter disease on MRI brain. Given that interven-
tions lowering total ceramide levels have been shown to
prevent atherosclerosis and insulin resistance in murine
models,35,36 modification of ceramides could represent
one attractive therapeutic option for prevention of vascu-
lar contributions to dementia, a premise that remains to
be tested.
In a small exploratory analysis within our cohort
(n = 48), an elevated ratio of C24:0 to C16:0 was associ-
ated with reduced ß-amyloid burden on PET-brain. Cera-
mides have been shown to stimulate ß-amyloid
formation, the pathological hallmark of AD, through reg-
ulating ß-site amyloid precursor protein cleaving enzyme
1 (BACE-1) activity,37,38 while inhibition of ceramide syn-
thesis results in reduced production of ß-amyloid.37–40
There is also evidence to support a role for ceramides in
tau phosphorylation. The enzyme protein phosphatase 2A
(PP2A), the primary regulator of tau phosphorylation in
Table 3. Ceramide ratios and MRI markers of structural brain injury.
TBV Hippocampal volume WMHV1 Covert brain infarcts
b  SE P-value b  SE P-value b  SE P-value OR (95% CI) P-value
Ceramide 24:0/16:0 0.03  0.05 0.44 0.001  0.001 0.46 0.05  0.02 0.02 0.98 (0.82–1.17) 0.79
Ceramide 22:0/16:0 0.07  0.05 0.17 0.0004  0.001 0.74 0.06  0.02 0.003 1.04 (0.87–1.24) 0.68
Model adjusted for age, age squared, sex, time from blood draw to MRI brain, systolic blood pressure, use of antihypertensive medication, preva-
lent cardiovascular disease, TC:HDL ratio, use of lipid-lowering therapies, and serum TG.
Abbreviations: SDU, Standard deviation units; SE, Standard error; TBV, total brain volume; WMHV, White matter hyperintensity volume.
1Natural log transformed.
ª 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 165
E. R. Mcgrath et al. Ceramides and Dementia
the brain, appears to be modulated by long-chain cera-
mides such as C18:0.41,42 In a murine model, inhibition
of serine palmitoyltransferase (a rate-limiting enzyme in
de novo ceramide synthesis) resulted in downregulation
of both cortical ß-amyloid and hyperphosphorylated tau
levels.43 Thus, it is conceivable that pharmacological inhi-
bition of long-chain ceramide synthesis could also slow
down or prevent the progression of AD dementia through
the prevention of ß-amyloid accumulation and tau phos-
phorylation.
Important strengths of our study include the use of a
community-based sample of cognitively healthy adults
confirmed to be free of dementia at baseline, a rigorous
and standardized approach to diagnosis of clinical
dementia and AD along with in-depth surveillance proce-
dures, a careful assessment of risk factors, and the large
number of individuals with measured plasma ceramide
concentrations compared to other studies to date. Fur-
thermore, the assay used to measure plasma ceramides
has shown high precision and accuracy with minimal
interbatch variability. Notable limitations include the
short follow-up interval (median 6-year follow up) with a
modest number of outcome events and the need for vali-
dation of these findings in other cohorts. Furthermore,
blood ceramide concentrations may change over time and
we were unable to assess stability of the ratios during fol-
low-up via repeat measurements. In addition, the Fram-
ingham Offspring Study is predominantly white and this
will limit the generalizability of our findings to other
races/ethnicities.
Conclusions
To our knowledge, this is the first study to demonstrate
that higher ratios of very long-chain to long-chain cera-
mides in the blood are associated with a reduced risk
of incident dementia and AD dementia. Our study pro-
vides evidence supporting the hypothesis that individual
ceramide species have differing biological roles in the
pathophysiology of dementia. If our findings are con-
firmed, circulating ratios of very long-chain to long-
chain ceramides may be useful biomarkers for predict-
ing future dementia risk among cognitively healthy
adults, several years in advance of clinically evident dis-
ease.
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